Author

Renato D Lopes

Professor afiliado da EPM/UNIFESP - Cited by 1,07,760 - Cardiologia

Biography

Professor Renato D. Lopes, MD, MHS, PhD, is a Professor of Medicine within the Division of Cardiology at Duke University Medical Center, Durham, North Carolina, USA, and a Professor of Medicine within the Divisions of Internal Medicine and Cardiology at the Federal University of Sao Paulo, Sao Paulo, Brazil. He completed his clinical training at the Federal University of Sao Paulo and his cardiology fellowship at the Duke Clinical Research Institute (DCRI), serving as Chief Fellow for the research training program.
Title
Cited by
Year
Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta …
HM Salah, SJ Al’Aref, MS Khan, M Al-Hawwas, S Vallurupalli, JL Mehta, ...Cardiovascular Diabetology 21 (1), 1-8, 2022202
37
2022
Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial
SD Pokorney, GM Chertow, HR Al-Khalidi, D Gallup, P Dignacco, ...Circulation 146 (23), 1735-1745, 222
20
2022
P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention
D Capodanno, U Baber, DL Bhatt, JP Collet, G Dangas, F Franchi, ...Nature Reviews Cardiology 19 (12), 829-844, 2022202
18
2022
Survival after invasive or conservative management of stable coronary disease
JS Hochman, R Anthopolos, HR Reynolds, S Bangalore, Y Xu, ...Circulation 147 (1), 8-19, 2023202
15
2023
Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
JW Eikelboom, SS Jolly, EP Belley-Cote, RP Whitlock, S Rangarajan, ...The Lancet Respiratory Medicine 10 (), 1169-1177, 2022202
12
2022
Ischemia with nonobstructive coronary arteries: insights from the ISCHEMIA trial
HR Reynolds, A Diaz, DD Cyr, LJ Shaw, GBJ Mancini, J Leipsic, ...Cardiovascular Imaging 16 (1), 63-74, 2023202
10
2023
Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
JW Eikelboom, SS Jolly, EP Belley-Cote, RP Whitlock, S Rangarajan, ...The Lancet Respiratory Medicine (12), 1160-1168, 2022202
10
2022
Rivaroxaban versus enoxaparin for thromboprophylaxis after major gynecological cancer surgery: the VALERIA trial: V enous thromboembolism prophyl A xis after gyneco L ogical p …
ALM Longo de Oliveira, RF de Oliveira Pereira, LB Agati, CM Ribeiro, ...Clinical and Applied Thrombosis/Hemostasis 28, 1060296221132556, 2022202
7
2022
Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillation
Z Hijazi, AP Benz, J Lindbäck, JH Alexander, SJ Connolly, JW Eikelboom, ...European heart journal 44 (3), 208-218, 2023202
6
2023
Rationale and design for the myocardial ischemia and transfusion (MINT) randomized clinical trial
JL Carson, MM Brooks, BR Chaitman, JH Alexander, SG Goodman, ...American Heart Journal 257, 120-129, 2023202
4
2023
Coordinated care to optimize cardiovascular preventive therapies in type 2 diabetes: a randomized clinical trial
NJ Pagidipati, AJ Nelson, LA Kaltenbach, M Leyva, DK McGuire, ...JAMA 329 (15), 1261-1270, 2023202
4
2023
Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of …
C Montalto, F Costa, S Leonardi, A Micari, JA Oreglia, P Vranckx, ...European Heart Journal-Cardiovascular Pharmacotherapy 9 (), 220-20, 20220
3
2023
Research opportunities in stroke prevention for atrial fibrillation: A report from a national heart, lung, and blood institute virtual workshop
AS Go, SM Al-Khatib, P Desvigne-Nickens, N Bansal, CD Bushnell, ...Stroke 54 (), e75-e85, 20220
3
2023
The ASCEND-NHQ randomized trial found positive effects of daprodustat on hemoglobin and quality of life in patients with non-dialysis chronic kidney disease
KL Johansen, AR Cobitz, AK Singh, IC Macdougall, RD Lopes, ...Kidney International 10 (6), 1180-1192, 20220
3
2023
Rivaroxaban in Outpatients with Mild or Moderate COVID-19: Rationale and Design of the Study CARE (CARE–Coalition COVID-19 Brazil VIII)
GBF Oliveira, PDMM Neves, HA Oliveira, DGM Catarino, LBO Alves, ...Arquivos Brasileiros de Cardiologia 10, e00431, 030
2
2023
Coordinating Cardiology clinics randomized trial of interventions to improve outcomes (COORDINATE)–Diabetes: rationale and design
AJ Nelson, NJ Pagidipati, MD Kelsey, M Ardissino, VR Aroda, ...American heart journal 56, -1, 030
2
2023
36-month clinical outcomes of patients with venous thromboembolism: GARFIELD-VTE
AGG Turpie, AE Farjat, S Haas, W Ageno, JI Weitz, SZ Goldhaber, S Goto, ...Thrombosis Research , 31-39, 030
2
2023
COVID-19 thrombotic complications and therapeutic strategies
AC Fanaroff, RD LopesAnnual Review of Medicine 74, 15-30, 030
2
2023
Apixaban or Warfarin in Patients with an On-X Mechanical Aortic Valve
TY Wang, LG Svensson, J Wen, A Vekstein, M Gerdisch, VU Rao, ...NEJM Evidence, EVIDoa300067, 030
2
2023
Defining strategies of modulation of antiplatelet therapy in patients with coronary artery disease: a consensus document from the Academic Research Consortium
D Capodanno, R Mehran, MW Krucoff, U Baber, DL Bhatt, P Capranzano, ...Circulation 147 (5), 1933-1944, 030
2
2023

Referred From: https://scholar.google.com.br/citations?user=4pPcOuUAAAAJ&hl=pt-BR

Cited by
Citations 107760
h-index 103
i10-index 487
Recommended Journals
Open Access Journals